Lucid Diligence Brief: SiranBio and GSK SA030 Licensing Agreement
Lucid Diligence Brief: SiranBio and GSK SA030 Licensing Agreement Professional…
Lucid Diligence Brief: Bayer to Acquire Perfuse Therapeutics for Up to $2.45B
Lucid Diligence Brief: Bayer to Acquire Perfuse Therapeutics for Up to $2.45B…
Lucid Diligence Brief: Apertura Gene Therapy and TSC Alliance Collaboration
Lucid Diligence Brief: Apertura Gene Therapy and TSC Alliance Collaboration…
Lucid Diligence Brief: Arrowhead ARO-PNPLA3 licensed to Madrigal
Lucid Diligence Brief: Arrowhead ARO-PNPLA3 licensed to Madrigal Professional…
Lucid Diligence Brief: Latus Bio $97 million Series A
Lucid Diligence Brief: Latus Bio $97 million Series A Professional audiences…
Lucid Diligence Brief: UCB acquisition of Candid Therapeutics
Lucid Diligence Brief: UCB acquisition of Candid Therapeutics Professional…
Lucid Diligence Brief: Axoft $55 million Series A
Lucid Diligence Brief: Axoft $55 million Series A Professional audiences only.…
Lucid Diligence Brief: Greywolf Therapeutics and Genomics strategic partnership
Lucid Diligence Brief: Greywolf Therapeutics and Genomics strategic……
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration for cancer trispecific HH160
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration…
Vaccines Today—April 30, 2026
This weekly update in Vaccines Research highlights recent regulatory actions,…
Lucid Diligence Brief: Chiesi to acquire KalVista Pharmaceuticals
Lucid Diligence Brief: Chiesi to acquire KalVista Pharmaceuticals Professional…
Lucid Diligence Brief: Teva to acquire Emalex Biosciences
Lucid Diligence Brief: Teva to acquire Emalex Biosciences Professional…